Fabienne Thomas - Concepedia

Author

Fabienne Thomas

Also Known As

C. Morse, F THOMAS, F Thomas, F. Thomas, Fabienne THOMAS, Fabienne Thomas, Fischer Thomas, Frédéric Thomas, Hoskins, J. M., Hoskins, Janelle M

212

Publications

3.1K

Citations

H-Index

Concepts

All Affiliations

Institut Claudius Regaud Université Toulouse III - Paul Sabatier Inserm Centre de Recherche en Cancérologie de Toulouse Institut Gustave Roussy

About

Fabienne Thomas is an author at Institut Claudius Regaud specializing in medicine, pharmacology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	27	1.2K
2	Health Sciences	5	5	151
3	Public Health	2	2	57
4	Engineering	1	1	11
5	Allergy	1	1	36

Fabienne Thomas

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors Birgit Geoerger, Darren Hargrave, Fabienne Thomas, Neuro-Oncology	2010	155
Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. I Héron, Fabienne Thomas, M Déro, The Journal of Clinical Endocrinology & Metabolism Pituitary GlandGrowth HormoneHuman GrowthMedicinePharmacotherapy	1993	118
<i><scp>UGT</scp>1A1</i> genotype and irinotecan therapy: general review and implementation in routine practice Marie-Christine Étienne-Grimaldi, Jean‐Christophe Boyer, Fabienne Thomas, Fundamental and Clinical Pharmacology PathologyPharmacotherapyAdvanced Colorectal CancerClinical GeneticsSystems Pharmacology	2015	108
New advances in DPYD genotype and risk of severe toxicity under capecitabine Marie-Christine Étienne-Grimaldi, Jean-Christophe Boyer, Christophe Béroud, PLoS ONE	2017	102
Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. Isabelle Morange, F de Boisvilliers, Philippe Chanson, The Journal of Clinical Endocrinology & Metabolism Acromegalic PatientsClinical TherapeuticPharmacologyClinical TrialsSc Injections	1994	101
Dendrogenin A drives LXR to trigger lethal autophagy in cancers Grégory Segala, Marion David, Philippe de Médina, Nature Communications	2017	101
In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR Diane Balin-Gauthier, Jean‐Pierre Delord, Philippe Rochaix, Cancer Chemotherapy and Pharmacology Different LevelMedicineAnti-cancer AgentCell BiologyCancer Treatment	2005	95
Effects of a slow‐release formulation of the new somatostatin analogue lanreotide in TSH‐secreting pituitary adenomas A Gancel, P. Vuillermel, A. Legrand, Clinical Endocrinology	1994	84
Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma Fabienne Thomas, Philippe Rochaix, Mélanie White‐Koning, European Journal of Cancer MedicinePharmacologyPharmacokinetic/pharmacodynamic RelationshipsHead And Neck CancerPharmacotherapy	2009	82
Pharmacokinetics of Oxaliplatin During Open Versus Laparoscopically Assisted Heated Intraoperative Intraperitoneal Chemotherapy (HIPEC): An Experimental Study Amélie Gesson-Paute, Gwénaël Ferron, Fabienne Thomas, Annals of Surgical Oncology Surgical OncologyMedicineMetronomic TherapyExperimental StudyPharmacotherapy	2007	77

Page 1